J&J beefs up neu­ro pipeline, bags a new de­pres­sion drug from Cere­cor in $45M deal

Eight months af­ter CERC-501 failed in a key mid-stage study for treat­ing nico­tine with­draw­al, Cere­core has out­li­censed the drug rights on de­pres­sion to phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER